REPL Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Replimune Group, Inc.

Robbins LLP is investigating allegations that Replimune Group misled investors about the efficacy and commercial viability of RP1, its lead product candidate. The notice signals potential securities-litigation risk and raises concerns over the clinical and investment case for Replimune's core oncology asset, though no financial damages, regulatory action, or clinical data were provided.